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Abstract
Background: Classical methods of gene product analysis such as binding assays (e.g., ELISA, protein chip
technology) are generally time-consuming, lab-intensive, less sensitive, and lack high-throughput capacity. In
addition, all existing methods used to measure proteins necessitate multiple divisions of the original sample and
individual tests carried out for each substance, with an associated cost for each test.
Method: Together with a small biotech company, we developed a new and innovative analytical detection system
based on homogenous time-resolved fluorescence (HTRF) technology. Our system facilitates the development of
immune assays that measure selective different analytes such as selected biomarkers in a small sample volume at
less than 20 min with a much higher sensitivity compared to common binding assay systems such as enzyme-
linked immunosorbent assay (ELISA). Recent advances of the application of this novel detection system combine
the power of miniaturization, microfluidics, better linear range, and faster quantification.
Results: The power of the HTRF technology offers great promise for point-of-care clinical testing and monitoring of
many important analytes such as disease-specific biomarkers in the nanogram level in different human body fluids
such as CSF, blood, serum, plasma, and saliva. The linear dynamical range of our HTRF assay was determined between
2.5 and 100 ng/mL. Precision and accuracy calculated for inter- as well as intra-assays was less than ± 10 %. Intra-assay
and inter-assay precision for high, medium, and low analyte concentrations show mean CV values less than ± 10 %.
Intra- and inter-assay accuracy for all three concentrations show mean recovery values of 80–120 %.
Conclusion: The aim of this work is to describe the development and establishment of this novel HTRF system that
allows the very fast detection and quantification of biomarkers in different human body fluids. Furthermore, a specific
antibody combination that assures a specific binding of the correct refolded autoimmune IgG is evaluated.
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Overview
The detailed biochemical characterization of possible
biomarkers as diagnostic relevant proteins by im-
munoassay has found utility in diverse applications
including biologic biomarker characterization and
identification. These applications sometimes require
the analysis of correct refolded autoimmune-proteins
present in low amounts in biological fluids, or the ac-
quisition of detailed information on the structure of
proteins expressed in heterologous systems such
blood, serum, plasma, or saliva.
Samples for analysis are routinely generated in aque-
ous solutions of suspension from different body fluids
that may contain a range of non-volatile salts, solvents,
albumins, immune globulins, and lipids. These contami-
nants or matrix proteins can impair the performance of
analytical techniques, where they cause a detrimental ef-
fect on specificity and sensitivity by interfering with ad-
ducts formation, and precipitation or modification. On
the other side, immunoassays such as enzyme-linked
immunosorbent assay (ELISA) are expensive and time-
consuming. ELISA normally requires 4–5 h until the re-
sult can be validated. Such ELISA immunoassays for
quantification of diagnostic relevant immunoproteins as
biomarkers have already been developed and described,
but most of them are too unspecific, expensive, and
time-consuming. Most of them are using monoclonal
capture and/or detection reagents directed against the
fragment-constant (Fc) part of the human IgG. However,
these assays cannot be used for molecules consisting
only of the antigen-binding fragment (Fab) of antibodies
or fusion proteins of Fab or a non-antibody protein be-
cause these molecules do not contain the epitope on the
Fc fragment. Furthermore, the antibodies directed
against human Fc exclude the simultaneous use of spe-
cific assay reagents which are expressed as Fc fusion
proteins to improve stability and expression yields since
they cross-react with these reagents. The development
of a generic immunoassay for the specific quantification
of correct refolded heterodimeric Fab is therefore highly
desired. Generally, there exists a great offer of immune
assays and it depends on the samples and the required
aims which one is the best one. One could be for
example ELISA, Western blot, flow cytometry or a
protein array, or immunohistochemistry or immuno-
fluorescence assay [1].
Autoimmune antibodies as selective biomarkers
Antibodies (IgG, IgM, IgA, IgE) are very specific re-
agents and are the specific cellular part of the immune
system. Antibodies are multifunctional molecules that
mediate the specific binding to the antigen and cause ef-
fector mechanisms like activation of the complement
system or signal transduction, so they are an important
part of the immune system [2, 3] and can be used as an
important tool to determine predictive biomarkers for
autoimmune diseases in human body fluids. Every anti-
body has four chains, two identical light chains and two
identical heavy chains that are both connected and stabi-
lized through non-covalent connections and covalent
connections like disulfide bridges. The N-terminal end is
the variable region and is responsible for the specific
antigen binding to the antibody. At the end of the vari-
able region is the hyper variable region or the so called
complementary determining region (CDR) which is re-
sponsible for the non-covalent binding of antigens. The
constant region is responsible for the effector mechan-
ism. So, antibodies are often figured as “Y” because they
have a long and a short arm. The junction between them
functions as a binding region and is named the Hinge
region [2, 4].
Today, most of the monoclonal antibodies are manu-
factured by fusion of a B cell and a myeloma cell of a
mouse. The aim is to combine the attributes of both, the
ability to produce specific immunoglobulins and the
ability to grow endlessly which make myeloma cells im-
mortal. For the fusion, polyethylene glycol (PEG) is used.
Monoclonal antibodies become more and more import-
ant as therapeutic agents so that until 2009, already 22
monoclonal antibodies have been approved for use. Also,
the fragments of the monoclonal antibodies, especially
the Fab, are preferred in therapeutic usage. A polyclonal
antibody is not as specific as a monoclonal one, but it is
much more sensitive [3–6]. For the preparation of an
antibody for a special immune assay, a conjugation of
the antibody for example with a special enzyme can be
done to get a signal. Favored systems are biotin or en-
zymes like alkaline phosphate and horseradish peroxid-
ase. Every manipulation can influence the antibody and
therefore may change the conformation or the binding
of the antigen [3, 7–9].
For a long time, antibody drug designers hypothesized
that antibodies could be used to engineer customized
and personalized therapeutics with pharmacologic prop-
erties. Designed antibodies could confer advantages like
better purity and improved quality and quantity of
goods. Physiochemical properties of therapeutic mole-
cules can be altered by fragmentation of antibodies. For
example, fragments with smaller size are able to pene-
trate into inaccessible tissues [10].
If immunoglobulins are digested with papain or pep-
sin, their amino acid binding can be divorced and three
fragments obtained (Figs. 1 and 2). Two of them are
equivalent and include the complete light chains that are
already associated with disulfide bridges to the CH1 do-
main of the heavy chains. This is also the reason why
these fragments still have the antigen-binding site and so
they are called fragment antigen-binding (Fab). Fab
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fragments are the oldest class of monoclonal antibody
fragment therapeutics and the most successful one (“ac-
counting 49 % of fragments” that entered clinical devel-
opment are Fabs). The third fragment consists of the
remaining heavy chains that are connected with disul-
fide bridges. This part is specific for each single iso-
tope, constant, and also independent from the
antibody specificity. It is named fragment-constant
region (Fc region). The antibody fragments have the
advantage of a similar binding specificity like the full
size immunoglobulin [2, 4, 10].
Fab fragments have only a part of the constant heavy
chain and that is why protein A and G are not able to
bind, which make Fab proteins a possible tool for ELISA
assays. Sometimes, negative side effects can occur be-
cause of effective ranges of the Fc fragment which are
eliminated by using only the Fab one. Furthermore, the
smaller size of antibody fragments allows a faster and
deeper penetration of tissues and tumors. The half-life
of the fragments can be increased as the half-life of the
whole antibody by covalent modifications with poly-
ethylene glycol or other large structures [11–14].
For example, the following fragments are used in ther-
apy: abciximab (ReoPro, Centocor/Johnson & Johnson) is
a Fab fragment of a chimeric antibody against platelet
glycoprotein IIb/IIIa, approved in 1994 as an adjunct to
prevent thrombosis during coronary artery catheterization
for ST-elevation myocardial infarction. Ranibizumab
(Lucentis, Genentech) is a humanized Fab directed against
vascular endothelial growth factor A, approved in 2006 as
a treatment for neovascular (wet) age-related macular
degeneration. Certolizumab pegol (UCB) is a pegylated
anti-TNFα Fab approved in 2008 for treatment of Crohn
disease [10].
Homogeneous time-resolved fluorescence technology
In the 1990s, the company Cisbio Bioassays, specialized
on immunoassays, invented homogenous time-resolved
Fig. 1 Structure of an antibody and the Fab fragment after digestion with pepsin/papain (taken from [10] and adapted)
Fig. 2 Overview of FRET technology: without and with close proximity between donor and acceptor (taken from [10] and adapted)
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fluorescence (HTRF) assay, a specialized immunoassay.
HTRF assay combines fluorescence resonance energy
transfer (FRET) technology with time-resolved (TR)
measurement to be an ideal platform for drug target
studies used in high-throughput methods [11, 12].
FRET (Fig. 2), also named Förster resonance energy
transfer, use the effect of energy transfer between two
fluorophores, a donor and an acceptor, when they are in
close proximity as for example when both are binding to
a different part of an analyte. Therefore, each partner
has to be coupled with a fluorescent label. The energy
transfer from the donor to the acceptor takes place by
an excitation of the donor by an energy source (e.g.,
flash lamp) that in close proximity triggers an energy
transfer towards the acceptor that emits specific fluores-
cence at a given wavelength [11–13]. FRET systems are
characterized by Förster’s radius distance with a FRET
efficiency of 50 %, and for HTRF, the radius is dependent
on the used acceptors between 50 and 90 Ǻ [12].
The donor-acceptor complex can be detected without
the need for physical separation from the unbound com-
ponents. That is why it is a homogeneous assay without
the need for further separation or washing steps. An-
other advantage of the HTRF assay is the time-resolved
measurement (Fig. 3) because some sample components
like buffers, proteins, and cell lysates influence the re-
sults with a negative background that is transient (life-
time in the nanosecond range) and that can be
eliminated with time-resolved measurement. The intro-
duced time delay of approximately 50 to 150 μs between
excitation and measurement allows a clearance of all un-
specific short-lived emissions. Contrary, acceptors emit
long-lived fluorescence and therefore long-lived emis-
sions [11–13] (Fig. 3).
Fluorescent partners have to fulfill multiple criteria.
The emission spectra must show non-overlapping re-
gions to measure each partner individually. A high
quantum yield and a fluorescence emission within a
region of the spectrum remote from that naturally pro-
duced by proteins are preferred. So, a combination of
different fluorophors is used. The donor consists of a
rare earth complex in which the lanthanide ion (euro-
pium or terbium) is attached in a macrocycle that
distributes robustness and long-lived fluorescence prop-
erties. Europium cryptates (Eu3+ cryptate; Fig. 4) devel-
oped by Prof. J.M. Lehn is a series of rare earth
complexes whose macrocycle is based on an embedded
trisbipyridine motif. This structure allows a transfer and
collection of energy to Eu3+ which releases this energy
in a specific fluorescent pattern that can be measured at
665 nm. The first acceptor was XL665, a phycobilipro-
tein pigment purified from red algae that is a hetero-
hexameric form of 105 kDa cross-linked for better
stability and preservation of its photophysical properties.
The now used acceptors (d2) are similar to XL665, but
100 times smaller, displaying a series of photophysical
properties close to XL665. The excitation spectra overlap
those of EU3+ cryptate emissions, and so, it is allowed to
excite from donor to acceptor whose maximum emis-
sion of 665 nm spans a region where HTRF cryptates do
not emit [11, 12].
Fig. 3 Time-resolved measurement of emission caused by energy
transfer from donor to acceptor (taken from [10] and adapted)
Fig. 4 Europium cryptate structure typically consists of a tris
bipyridine macrocycle in which the lanthanide ion is tightly
embedded (taken from [10] and adapted)
Einhorn and Krapfenbauer The EPMA Journal  (2015) 6:23 Page 4 of 13
Long signal stability is another benefit that includes
read time flexibility, the ability to perform kinetic studies
and increased sample compatibility. The robustness can
be explained by the photophysical and chemical stability
of the involved fluorophores. The cryptate structures re-
sist harsh conditions or additives, and the europium
cryptate resistance can be enhanced by adding fluoride
ions. Another positive property of cryptates is that they
do not photo bleach (the disappearance of fluorescence
emission after repeated excitation) and that the accep-
tors are compatible with a wide range of conditions [11].
For measuring two emissions, wavelengths are used, 620
and 665 nm, which allow the ratiometric reduction of data
that can reduce well-to-well variations. It allows the meas-
urement of the donor and the acceptor wavelength
whereby donor emission at 620 nm is taken for internal
reference, while acceptor emission at 665 nm is used as
indicator of the biological reaction being assessed [12].
Summarized, HTRF assay is an immune assay that
combines homogeneity, time-resolved measurement
without interference of other components, the possibility
of automatization because there is no need for washing
or separation steps and the FRET technology. Overall,
HTRF is a highly specific, robust technology for the de-
tection of molecular interactions and is widely used for
drug development; with a standard curve, quantification
is also possible [12].
Sources of error
All existing immune assays share the sensitivity to inter-
ferences. That can be cross reactions, unspecific bind-
ings, matrix effects, and interactions between the analyte
and antibodies with disrupting substances. Fluorescence-
labeled antibodies are further influenced by interactions
between proteins of the sample and the fluorescence
dye. Labeling with enzymes can lead to unspecific bind-
ings, and the immobilization may lead to structural
changes [14].
Interference because of unspecific labeling can be in-
duced by unspecific binding of the labeled antibody to
the surface. This problem could be avoided by blocking
the surface before detection [14]. Furthermore, the use
of the wrong blocking buffer or the inadequate blocking
process leads to unspecific bindings. Fluorescent dyes
can change the binding properties, that leads to an in-
creased surface, catching of an antibody or foreign pro-
tein, and consequently to a wrong positive measurement
signal or high background [15].
Another source of interference could be the choice of
antibodies. Generally, the quality of highly purified anti-
bodies should be guaranteed by the manufacturer. Espe-
cially for sandwich ELISA, it should be ensured that the
secondary antibody (for example goat anti-rabbit-
peroxidase-labeled) does not bind to the analyte [14, 15].
Matrix effects are defined as the sum of the whole num-
ber of effects of all sample components that influence the
measurement of the target analyte. Causes of risk are sam-
ple proteins that are candidates for unwanted interactions
with the analyte or the antibodies [14].
Interferences because of chemicals and buffers are an
important, but often ignored, point. Viscosity, salt concen-
tration, and pH directly influence binding between analyte
and antibody. Antibody bindings normally prefer physio-
logical conditions at about pH 6–8 and a NaCl concentra-
tion of about 150 mM. Furthermore, it is beneficial if the
matrix of standard and sample is the same [14].
Further problems can occur with cross reactions and
unspecific bindings. Cross reactions are defined as the
ability of an antibody to bind more than one target
structure. The cross-reacting agent is known. Unspecific
binding describes the binding of a substance that is
available with a higher concentration compared with the
target analyte [14].
Proteins and endogenous parts of proteins may also in-
fluence the measurement. Natural proteins like albumin
or lysozyme have the ability to bind other proteins so no
further connection with antibodies is possible. Unspe-
cific bindings and cross-contaminations are the conse-
quences. Endogenous proteins can mask the analyte or
interfere the binding with an antibody. To determine the
stability of the sample, many conditions have to be con-
sidered like the sample taking or the age of the sample.
The storage conditions, temperature sensitivity, and the
repeated freezing and thawing of the sample are further
important points for interferences and should be investi-
gated [14, 15].
Finally, interferences because of human antibodies
against immunoglobulins of animal origin and hetero-
phile antibodies which have false positive signals as con-
sequence have to be mentioned [15].
So, there exist many obstacles which can influence an
immune assay. To reduce interferences, they have to be
identified and the reasons have to be detected. Finally,
an appropriate strategy has to be established to optimize
the assay as good as possible [14].
Hook effect
The Hook effect (Fig. 5) is a false negative result. The
effect appears in highly concentrated samples which
are mixed directly with the assay antibodies (for ex-
ample used by the HTRF assay). In that case, the
high concentrations of the analyte, which exceed the
concentration of the used assay antibodies, saturate
both antibodies (started at the so named Hook point).
The high concentrations simulate a lower concentra-
tion that leads to an underestimation of the true
value. To avoid the influence of Hook effect and its
impact on the results, higher concentrations of the
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assay antibodies or a higher dilution of the used sam-
ples can be helpful [15].
Steps for evaluation of the HTRF immune assay
From the first development of an assay to the con-
tinuous use, the degree of stringency required in data
analysis was underestimated, and consequently, many
publications with questionable results and quality
have been issued. With the ICH guidelines (ICH-Q2A
and ICH-Q2B), a standardized and exact characterization
and validation guideline was introduced [16].
In the course of characterization and validation
studies, a number of key issues in research and devel-
opment must be implemented. “The complexity of an
analytical validation should reflect the aim of the
analysis and thus has to be in accordance with the
intended use.” So, validation is comparable with a
demonstration that a method can fulfill its designated
duty [16].
Specificity, selectivity, accuracy, precision, recovery,
calibration curve, and stability of analyte spiked in sam-
ples are some examples that are performed during this
work.
Specificity “is the ability to assess unequivocally the
analyte in the presence of components which may be ex-
pected to be present”. With the specificity, it is possible
to assure the correct detected analyte and the difference
between the test method value and the theoretical value
can be described. It is a combination of identification
tests, assay, and impurity tests [16, 17].
Selectivity “is the ability of an analytical method to
differentiate and quantify the analyte in the presence of
other components in the sample [18].” The selectivity is
determined with Western blot and a specific antibody.
Accuracy “describes the closeness of mean test results
obtained by the method to the true value (concentration)
of the analyte. Accuracy is determined by replicate ana-
lysis of samples containing known amounts of the analyte
[18].” The accuracy is comparable with the calculated re-
covery results of standard curves done by ELISA and
HTRF experiments. “The mean value should be within
15% of the actual value except at LLOQ, where it should
not deviate by more than 20 % [18].”
Precision “describes the closeness of individual mea-
sures of an analyte when the procedure is applied re-
peatedly to multiple aliquots of a single homogeneous
volume of biological matrix [18].” Here, the precision
coefficient of variation [%] is measured with different
dilutions in triplicate and is done with different con-
centrations with ELISA and HTRF assay. “The preci-
sion determined at each concentration level should not
exceed 15 % of the coefficient of variation (CV) except
for the LLOQ, where it should not exceed 20 % of the
CV [14].” So, the precision describes the assay vari-
ability and expresses the closeness of agreement be-
tween many measurements from multiple sampling of
the same sample [16].
Recovery “is the detector response obtained from an
amount of the analyte added to and extracted from the
biological matrix, compared to the detector response ob-
tained for the true concentration of the pure authentic
standard.” “Recovery of the analyte need not be 100%,
but the extent of recovery of an analyte and of the in-
ternal standard should be consistent, precise, and
Fig. 5 Hook effect and consequences (taken from [10] and adapted)
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reproducible.” The acceptable range of recovery is lim-
ited to ±20 % of 100 % [18].
Calibration/standard curve: “A calibration (standard)
curve is the relationship between instrument response
and known concentrations of the analyte [18].” For each
blot or plate, a separate standard curve is produced in
order to compare the results of the analyte with the
standard using the same conditions (see 4.2 and 4.3).
“The lowest standard on the calibration curve should be
accepted as the limit of Quantification” (LLOQ) [16, 18].
So a range for linearity, evaluated by visual inspection of
a plot of signals as a function of analyte concentration,
with a R2 > 0.98, is established. The acceptable range be-
tween an upper and lower quantitation limit (QL), that
is the highest and lowest possible measurements with an
acceptable precision and accuracy, depends on the
intended application of the procedure [16, 17].
Stability: “Drug stability in a biological fluid is a func-
tion of the storage conditions, the chemical properties of
the drug, the matrix, and the container system [18]”. The
standard with known concentration is spiked in samples
to test the influence of matrix effects and the conse-
quential stability. Therefore, the recovery is calculated
and compared with the known standard concentrations.
Methods
Homogenous time-resolve fluorescence (HTRF) assay
combines fluorescence resonance energy transfer (FRET)
technology with time-resolved (TR) measurement. Dif-
ferently to an ELISA assay, no immobilization, washing,
or separation is necessary. So, for a HTRF, only three
compartments are necessary, the analyte, the donor anti-
body with Eu3+ cryptated, and the acceptor with d2, an
enhancement of XL665 cryptate. They can be mixed in
the well of the microtiter plate, and after a short incuba-
tion time of a few hours, the detectable emission caused
by an energy transfer from donor to acceptor is detect-
able and stable over a long period of time [12] (Table 1).
The monoclonal Abcam antibody and the polyclonal
antibody Novus are used as donors labeled with euro-
pium cryptate (Eu3+) that allows a collection and
transfer of energy to Eu3+ which releases this energy
in a specific fluorescent pattern that can be measured
at 620 nm. As acceptor, polyclonal Novus antibody is
used, marked with d2 that possesses a series of
photophysical properties similar to XL665 with 100
times smaller organic structure and is measured at
665 nm.
The dilution buffer is used to dilute the samples and
prepare the standard curve. The conjugate buffer is used
to prepare the HTRF conjugates (Tables 2, 3, 4, and 5).
Working procedure
The HTRF analysis involves four steps:
1. Dilution of the samples with dilution buffer (it is also
possible to use 1xTBST buffer for dilution to
compare with ELISA assay)
2. Dilution of the antibodies with reconstitution buffer
3. Mixing of the antibody and the sample in the wells
and incubation for ~20 min
4. Measuring the plate
For 384 plates:
 Use 384 low volume white plate
 Add 10 μL sample or diluent buffer for negative
control
 Add 5 μL pAb1-d2 conjugate
 Add 5 μL mAb2-Eu3+ cryptate conjugate/pAb1-Eu3+
cryptate conjugate
 Incubate at room temperature
 Measuring: in the period of time at 317 nm
(reference 665 nm/620 nm) with Tecan Safire 2
plate reader
It is possible to shorten the working process by
mixing the two antibodies before adding them to the
well (Tables 6 and 7). For measuring, Safire 2 from
Tecan is used with the Magellan Software (Tecan ver-
sion 7.1) for evaluation. Two sequential measure-
ments should be carried out: at 620 nm for the
cryptate emission and at 665 nm for the specific sig-
nal emitted by the acceptor (XL665 or d2). The ratio
of the two fluorescence intensities 665/620 (acceptor/
donor) enables the calculation of Delta F [%] which
represents the relative energy transfer rate for each
sample. Safire 2™ readers must be appropriately be
configured for HTRF readout by setting up the meas-
urement conditions in the “multilabeling” function of
Magellan software. In particular, these parameters
should be entered as below. The reader only allows
Table 1 Antibodies used for HTRF
Manufacturer/name Specific for Format Labeled as Catalog number
Abcam Correct refolded Hinge
region
Mouse monoclonal [2A11] to human IgG Donor: conjugated to Eu3+ cryptate Ab7497
Novus Light chain Goat anti-human IgG antibody; polyclonal Acceptor: conjugated to d2 AP003CUS01
Novus Light chain Goat anti-human IgG antibody; polyclonal Donor: conjugated to Eu3+ cryptate AP003CUS01
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high performance for the used HTRF measurement
when the HTRF is run with white plates. No special




Results of homogenous time-resolved fluorescence assay
Actually, the development of the HTRF assay is similar
to the ELISA development.
For development, the following experiments have been
performed:
 Restriction of the detection range for different
standards and definition of the linear range and the
preferred incubation time
 Accuracy and precision of the linear range
 Comparison of the possible antibody pairs for the
specific determination of the biomarker as target protein
 Measuring of different biomarker proteins in different
concentrations and comparison with ELISA results
 HTRF spike-in experiments to determine possible
matrix effects
 Some experiments to improve the HTRF assay and
to minimize Hook effect
With the results of the measured wavelengths, calcula-
tions can be done (S = standard variance; M =mean of
delta OD; k = gradient; d = y-axis intercept). First, the ra-




ΔF ¼ mean ratiosample−mean rationegative
mean rationegative
 100
So, the calculated fluorescence ratio ΔF [%] represents
the time-resolved fluorescence of the aim energy transfer















5 ¼ c  dilution factor
1000
Recovery %½  ¼ sample concentrationcalculated
sample concentrationtheoretical
 100
Table 2 Ordernumber from CisBio of the antibodies and buffers







Stock solution 211μg/mL 497μg/mL – –
Ref. # (Cisbio) 64CUSKAYE 64CUSDAYE 62DL3DDD 62RB3RDD
Table 3 Further reagents used for HTRF
Reagents Manufacturer
HQ water In-house
1 M Sodiumchlorid (NaCl) Merck
Drug substance proteinX [1 mg/mL] BIRCV/BPA PSDP
Drug substance protein [4.3 mg/mL] BIRCV/BPA PSDP
1x TBS-casein block/diluent BioFX Laboratories
Tween 20 Sigma Aldrich
Excitation wavelength 317 nm
Excitation bandwidth 20 nm
Emission wavelength 620 nm
Emission bandwidth 10 nm
Number of reads 100
Lag time 60 μs
Integration time 500 μs
Excitation wavelength 317 nm
Excitation bandwidth 20 nm
Emission wavelength 665 nm
Emission bandwidth 10 nm
Number of reads 100
Lag time 60 μs
Integration time 500 μs
Table 4 Dilution factor to prepare the working solution from
stock solution and concentration of the working solution









pAB1-Eu3+ 576 0.34 ng/μL 0.085 ng/μL
pAb1-d2 124 4 ng/μL 1 ng/μL
mAb2- Eu3+ 517 0.408 ng/μL 0.102 ng/μL
Table 5 Reagent preparation, as prepared in the best pair work
of CisBio [10]









pAB1-Eu3+ 576 0.34 ng/μL 0.085 ng/μL
pAb1-d2 124 4 ng/μL 1 ng/μL
mAb2- Eu3+ 517 0.408 ng/μL 0.102 ng/μL
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Restriction of the detection range for different stan-
dards and definition of the linear range and the pre-
ferred incubation time.
For the determination of a steady standard curve of
standard proteinX and standard protein, an antibody
combination of the monoclonal antibody Abcam
labeled with europium (Eu3+) cryptate and specific to
the Hinge region as donor and as second antibody
the polyclonal Novus labeled with d2 and binding the
light chain as acceptor is used. The sample and anti-
body mix volume (=5 μL donor and 5 μL acceptor
antibody) is 10 μL.
Figures 6 and 7 show the results of different proteinY
concentrations at different times. So, it is possible to
define the necessary incubation time that allows stable
results over a long period. For proteinY, an incubation
time of 3 or 4 h seems to be sufficient, and for proteinX,
a maximum value is reached after 3 h of incubation.
These results show significant shorter incubation time
compared to the ELISA incubation times of 13 to 15 h
(Fig. 8).
Furthermore, Figs. 7 and 8 compare results of
HTRF measured from 1 and 4 h and one measure-
ment after 24 h which presents just little declines
after 24 h. So, the HTRF assay is stable, analyzable,
and evaluable over a long period of time without any
bleaching effects.
Comparison between ELISA and HTRF
Table 8 shows an overview about some summarized
example measurements to show the final trends of
both assays. Noticeable is the high difference between
the linear ranges of the assays. ELISA has mostly a
stable linearity between 14–1 ng/mL for proteinX and
10–1 ng/mL for proteinY. This range is approved by
experiments to determine the accuracy and the
precision. Inter-assay experiments are comparisons
between the same sample and analyte, done on differ-
ent microtiter plates, whereas intra-assays are between
the same samples with different dilutions done on the
same plate. The inter precision for HTRF assay seems
to be higher. It can be influenced by the higher con-
centration range where the analyses are performed,
but apart from this for both assays, it is below the
limit of 20 %. For the accuracy, both assays are per-
formed in the acceptable range of 100 ± 20 %, but the
HTRF assay is just a little closer to 100 %. The intra-
assay results of one example analyte produce for both
assays nearly the same percentages of accuracy and
precision.
Further possible positive/negative points are listed at
Table 9 There, it is obvious that HTRF assay has some
further advantages compared with ELISA. It is
homogenous, so no washing steps are necessary that
shortens the working and process time. The time-
resolved measurement eliminates possible fluorescence
background caused by other proteins, the analyte, or the
donor antibody. Furthermore, ELISA reactions caused
by consumed substrate are just stable for 30 min,
whereas the HTRF fluorescence is constant for many
hours and loses intensity just after 24 h, so any bleaching
effects can be denied. Another positive point of HTRF is
the possibility to use the assay with 384 well plates and
small volumes of just 10 to 2.5 μL per analyte/antibody
mix compared to 100 μL volume per analyte/antibody
needed for ELISA 96-well plates. One possible disadvan-
tage of HTRF is the limitation caused by the Hook effect
that can negatively influence results of higher concen-
trated samples. With the limitation of the volume of
analytes, this problem can be solved. All in all, these ad-
vantages are the reason why HTRF just needs 4–5h of
process time (1 h for preparing samples/standard, 3–4 h
for incubation), and ELISA needs much longer 15–16 h
(12 h first antibody incubation, 1 h preparing samples/
standard, 1 h blocking, 1 h second antibody incubation,
washing, and developing). So, the analyzed sample per
well costs, that are very interesting for the industry, can
be reduced from 5–7 € for ELISA to 0.5–0.7 € for HTRF
(calculated costs just contain material costs).
Results
A constant increasing development of fragmented
therapeutic monoclonal antibodies in the biomarker
research and personalized medicine requires careful
detection and quantification methods of antibody
drug candidates. For many personalized therapeutic
antibodies, no methods are available because of a lack
of specific assay reagents. In this work, the develop-
ment of a novel and very specific immuno assay for
quantification of correct refolded Fab proteins by
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implementation of homogenous time-resolved fluores-
cence (HTRF) technology is done and compared with
enzyme-linked immunosorbent assay (ELISA).
During this work, many results are collected to com-
pare different immune assays and evaluate the benefits
and disadvantages of all of them.
At first, Western blot is used to test different anti-
bodies to find the specific one that can be used in fur-
ther immune assays as a specific and universal detection
antibody. The unlabeled monoclonal antibody of the
company Abcam that is specific to the Hinge region of
the Fab proteins combines high specificity and a generic
applicability.
After a specific antibody is found, another immune
assay is tested. ELISA has many possibilities of
antibody-antigen combinations. Since Abcam is not
labeled, a sandwich ELISA is done. By analyzing the
linearity of the ELISA with two proteins, ranges with
high regression coefficients (of about 0.99) are ob-
tained. For proteinX, the range is between 36 and
1 ng/mL, and for proteinY, between 10 and 1 ng/mL.
With these results, it can be seen that the linearity of
the ELISA is restricted to a small range with low
concentrations. The accuracy tested for this range is
88–99.4 % for proteinX and 80.9–95.9 % for proteinY
in most cases. Furthermore, the precision of both
proteins is tested in any kind of analysis by calculat-
ing the coefficient of variation (CV). For proteinX,
the precision range is about 5.7–9.9 %, and for pro-
teinY, 5.9–11.4 %. Accuracy and precision are for
both proteins in the acceptable range defined by the
FDA. Experiments, done with fermentation samples
and different dilutions, show that the concentrations
are comparable with little variations and coefficients
of variation less than 15 %. Spike-in experiments to
determine a range without matrix effects and to de-
fine stability are further tested parameters. ProteinX
has acceptable recovery results between 40 and 1 ng/
mL and coefficients of variation less than 20 % that
means a high stability in this range which is just a
Table 8 Comparison of the final results of ELISA and HTRF assay
ELISA HTRF
proteinX proteinY proteinX proteinY
Linear range 36–1 ng/mL 10–1 ng/mL 100–2.5 ng/mL 50–3.6 ng/mL
Lower limit of detection (LLOD) 2.5–1 ng/mL 1 ng/mL 3.6–2.5 ng/mL 3.6 ng/mL
Upper limit of detection (ULOD) 36 ng/mL 10 ng/mL >100 ng/mL 50 ng/mL
Inter-assay precision 5.71–9.9 % (n = 6) 5.9–11.4 % (n = 6) 5.7–16 % (n = 6) 4.3–13.4 % (n = 6)
Inter-assay accuracy 87.9–99.4 % (n = 6) 80.9–95.9 % (n = 6) 90–93 % (n = 6) 87.5–98.1 % (n = 6)
Intra-assay precision 2.1–3.7 % (n = 3) 8.1–10.3 % (n = 3) 3.3–9.5 % (n = 3) 2.9–10.7 % (n = 3)
Intra-assay accuracy 92.9–97.9 % (n = 3) 88–95.9 % (n = 3) 101–105 % (n = 3) 96.6–99.2 % (n = 3)
Fig. 6 Standard proteinY with different concentrations and different incubation times; standard curve after 1 h (diamond), standard curve after
2 h (square), standard curve after 3 h (triangle)
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little divergent to the linear range. The range of pro-
teinY is 10 and 1 ng/mL and so exactly comparable
with the linear range and also with low coefficients of
variation about 15 %.
HTRF assay combines a universal homogenous immune
assay with the properties of the FRET-effect and a time-
resolved measurement. HTRF is used to evaluate the re-
sults of ELISA assay and to make an enhanced immune
assay available. First, the linear range is determined; for
the upper limit of proteinX, more than 100 ng/mL are
useable and the linearity is stable until about 3.6–2.5 ng/
mL. For proteinY, the range of 50–3.6 ng/mL is linear. So,
with HTRF higher linear ranges are available, and also, the
accuracy for proteinX of about 90–93 % and for proteinY
of about 87.5–98.1 % lies in the favored guideline of 100 ±
15 %. The precision is just a little bit higher as for ELISA
and lies between 5.7 and 16 % for proteinX and between
4.3 and 13.4 % for proteinY. By measuring samples with
high concentrations (about 1 mg/mL), high variations be-
tween HTRF and ELISA assay can be observed, that can
be caused by a great influence of high dilution factors and
consequently dilution errors. With lower concentrations,
a high reproducibility is possible (for example a sample
about 100 ng/mL). Spike-in experiments show for pro-
teinX acceptable recovery values of less than ±15 % of
100 %, even with concentrations of about 400 ng/mL, and
for low concentrations of about 3–2 ng/mL, just little vari-
ations out of the favored guideline of ±20 %. The recovery
of proteinY shows results in an acceptable range from 50
to 1 ng/mL with less than 20 % variation.
Fig. 7 Different incubation times for proteinY using three different concentrations
Fig. 8 Different incubation times for proteinX using three different concentrations
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Finally, some problems like the Hook effect are tried to
be solved by a combination of different volumes of ana-
lyte and antibodies to minimize the influence of Hook
effect and to extend the available linear range of HTRF.
While for proteinX no noticeable changes are observed,
the useable linear concentration range of proteinY
doubles.
Furthermore, a limitation of the used volumes until
2.5 μL of antibody mix and 2.5 μL of analyte shows little
differences of the slope compared with the normal cre-
ated curve (10 μL antibody mix + 10 μL protein), but
also linear curves with acceptable R2 of 0.99. That initial-
izes the facility to miniaturize the needed assay volumes.
The conclusion of the comparison of ELISA and
HTRF assay is that both have some useable and irre-
placeable abilities. For lower concentrated samples
where high precision and accuracy are assumed and
process times with volumes of about 100 μL per well
are available, ELISA is suitable to bring a representa-
tive result. If an immune assay with minimal sample
volume, the ability to measure 384 samples simultan-
eously, and less process time of about 4 h is preferred
that shows good precision, linearity, and accuracy as
well in high and low concentrations, the generic and
homogenous HTRF assay should be the method of
first choice.
Further, necessary steps would be to try to stabilize
both methods even more to eliminate all possible in-
fluences like buffer effects or wrong antibody dilu-
tions to get results without any kind of aberrations
and errors. Therefore, many little facts like any kind
of buffer or different dilutions of the antibody and
also different plate types have to be tested if they in-
fluence the measurement. Automatization of both as-
says (for ELISA just the sample/standard dilution step
could be automated) with a robot could be an advan-
tage to avoid handling/pipette errors, to decrease
working time, and to improve miniaturization. The
current technology and paper conform with the rec-
ommendation of the “EPMA White Paper” [19].
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